Can a daily pill offer Long-Term hope for Alzheimer's?
NCT ID NCT07757204
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This trial investigates the long-term safety of buntanetap, an experimental daily pill, in people with Alzheimer's disease who have already taken the drug in a previous study. About 400 participants will receive buntanetap 30 mg daily, with researchers tracking side effects and serious adverse events over time. The goal is to see if the drug remains safe for extended use, which could support its potential as a future treatment for Alzheimer's.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- buntanetap (also known as posiphen), taken as a 30 mg daily pill
- What this could lead to
- If successful, this could support buntanetap as a long-term treatment option for Alzheimer's disease, potentially slowing cognitive decline.
- What could go wrong
- This is an open-label extension study focused on safety, not efficacy, so it may not confirm whether the drug truly helps. Long-term use may still reveal side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DEMENTIA (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.